Vaxxas

Hamilton, Australia

Vaxxas develops needle-free HD-MAP patches that use microprojections to deliver medicine directly to immune cells beneath the skin.

$31.9M raised

Aug 2025

Series D

Biotechnology Health Care Medical Device

Top Investors

Bill & Melinda Gates FoundationWellcome TrustBrandon CapitalOneVenturesBiomedical Advanced Research and Development Authority (BARDA)

Founder Contacts

19,000+ verified contacts

Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Vaxxas

How much funding has Vaxxas raised?

Vaxxas has raised $31.9M in total funding. The most recent round was Series D. The last funding was announced in August 2025.

Who are Vaxxas's investors?

Vaxxas's investors include Bill & Melinda Gates Foundation, Wellcome Trust, Brandon Capital, OneVentures, Biomedical Advanced Research and Development Authority (BARDA).

Where is Vaxxas headquartered?

Vaxxas is headquartered in Hamilton, Australia.

What does Vaxxas do?

Vaxxas develops needle-free HD-MAP patches that use microprojections to deliver medicine directly to immune cells beneath the skin.

What stage is Vaxxas at?

Vaxxas is at the Series D stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated August 25, 2025.

MLA

"Vaxxas — Funding & Investors." VCBacked, August 25, 2025, https://www.vcbacked.co/company/vaxxas. Accessed June 17, 2026.

APA

VCBacked. (2025). Vaxxas — Funding & Investors. Retrieved June 17, 2026, from https://www.vcbacked.co/company/vaxxas

Wikipedia (cite web)

{{cite web |title=Vaxxas — Funding & Investors |url=https://www.vcbacked.co/company/vaxxas |website=VCBacked |access-date=June 17, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated August 25, 2025.

Similar Companies in Biotechnology